CUBIST PHARMACEUTICALS INC
Sector: Drug Manufacturers Other
Latest Quote @ Wed Jun 6 18:53:40 (15 min delayed)
Last Day's Data
Cubist Pharmaceuticals, Inc. engages in the research, development, and commercialization of products for anti-infective and acute care needs market. Its principal product, Cubicin, is approved in the United States for the treatment of skin and skin structure infections caused by certain gram-positive bacteria. The company's pipeline includes HepeX-B, a monoclonal antibody biologic that is in second of two Phase 2 trials, for the prevention of infection by Hepatitis B virus in liver transplant patients, as well as research efforts focused on members of the lipopeptide class of molecules. Cubist has a licensing agreement with XTL Biopharmaceuticals, Ltd., for the development and commercialization of HepeX-B. The company was founded in 1992 and is headquartered in Lexington, Massachusetts.